Franc Brisebois

Managing Director and Senior Analyst at Oppenheimer & Co. Inc.

Franc Brisebois is a Managing Director and Senior Analyst at Oppenheimer & Co. Inc., specializing in the coverage of biotechnology and biopharmaceutical companies with a focus on subsectors including ophthalmology, audiology, pain/CNS, cannabis derivatives, and digital medicine. He covers over 25 companies such as Centessa Pharmaceuticals, Savara, Sensei Biotherapeutics, Abeona Therapeutics, Ovid Therapeutics, and Tarsus Pharmaceuticals, with a documented success rate of 31% and an average return per rating of -7.5%, although some standout stock calls, such as Avadel Pharmaceuticals and DermTech, have generated single-trade returns exceeding 450% and 23% respectively. Brisebois started his analyst career at Summer Street Research Partners, then spent five years at Laidlaw Capital Markets and later joined Craig-Hallum Capital as Senior Research Analyst before joining Oppenheimer in 2020. He holds a BA in Molecular Biology from Colgate University, an MS in Pharmaceutical Sciences from the University of Montreal, is registered with FINRA, and holds relevant securities licenses.